A radiopharmaceutical for imaging areas of lymphocytic infiltration:123I-interleukin-2. labelling procedure and animal studies

Nuclear Medicine Communications

Volumn 13, Issue 10, 1992, Pages 713-722

  Signore, A ^a   Chianelli, M ^a   Toscano, A ^b   Monetini, L ^a,b,c,d   Ronga, G ^a   Nimmon, C C ^d   Britton, K E ^d   Pozzilli, P ^b   Negri, M ^c  

^a USL 31   (Italy)

^b Endocrinologia I ^*  (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE OXIDASE; INTERLEUKIN 2; IODINE 123; LACTOPEROXIDASE; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; GENETIC SUSCEPTIBILITY; IMAGING; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PANCREAS; SCINTILLATION CAMERA; TECHNIQUE;

ANIMAL; FEMALE; INTERLEUKIN-2; IODINE RADIOISOTOPES; ISOTOPE LABELING; LEUKEMIA, LYMPHOCYTIC; LEUKEMIC INFILTRATION; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; PANCREAS; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0026785027     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-199213100-00003     Document Type: Article

References (39)

1. Rubbert A, Manger B, Lang N et al. Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer 1991; 49: 25-31.
2. Kirkman RL, Barrett LV, Gaulton GN et al. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358-62.
3. Thedrez P, Paineau J, Jacques Y et al. Biodistribution of an anti-interleukin 2 receptor monoclonal antibody in rat recipients of a heart allograft, and its use as a rejection marker in gamma scintigraphy. Transplantation 1989; 48: 367-71.
4. Bottazzo GF, Dean BM, McNally JM et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl Med 1985; 313: 353-60.
5. Wall JR, Baur R, Schleusener H et al. Peripheral blood and intrathyroidal mononuclear cell populations in patients with autoimmune thyroid disorders enumerated using monoclonal antibodies. J Clin Endocrinol Metab 1983; 56: 164-8.
6. Buchan G, Barrett K, Fujita T et al. Detection of activated Tcell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol 1988; 71: 295-301.
7. Lemm G, Warmatz H. Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation in by synovial fluid lymphocytes in rheumatoid arthritis. Clin Exp Immunol 1986; 64: 71-9.
8. Selby WS, Janossy G, Bosil M et al. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 1984; 25: 32-40.
9. Issekutz T, Chin W, Hay JB. Measurement of lymphocyte traffic with 111-indium. Clin Exp Immunol 1980; 39: 215-21.
10. Peters AM, Saverymuttu SH, Reafy HJ et al. Imaging of inflammation with 111-indium tropolonate labelled leucocytes. J Nucl Med 1983; 24: 39-14.
11. De Schrijver M, Streule K, Senekowitsch R et al. Scintigraphy of inflammation with nanometer-sized colloidal tracers. Nucl Med Commun 1987; 8: 895-908.
12. Streule K, De Schrijver M, Fridrich R. 99Tcm-labelled HSA-nanocolloid versus 111-In oxine-labelled granulocytes in detecting skeletal septic process. Nucl Med Commun 1988; 9: 56-67.
13. Fischman AJ, Rubin RH, White JA et al. Localization of Fc and Fab fragments of nonspecific polyclonal IgG at sites of inflammation. J Nucl Med 1990; 31: 1199-205.
14. Lind P, Langsteger W, Koltringer P et al. Immunoscintig- raphy of inflammatory processes with a technetium-99m- labeled monoclonal antigranulocyte antibody (MAb BW 250/183). J Nucl Med 1990; 31: 417-23.
15. Block D, Ogtrop MV, Arndt JW et al. Detection of inflammatory lesions with radiolabelled immunoglobulins. Eur J Nucl Med 1990; 16: 303-5.
16. Oyen WJG, Claessens RAMJ, van Horn JR et al. Scintigraphic detection of bone and joint infections with Indium- 111-labeled nonspecific polyclonal human immunoglobulin G. J Nucl Med 1990; 31: 403-12.
17. Rubin RH, Fischman AJ, Nedelman M et al. Radiolabelled, nonspecific, polyclonal human immunoglobulin in the detection of focal inflammation by scintigraphy: comparison with gallium-67 citrate and technetium-99m-labelled albumin. J Nucl Med 1989; 30: 385-9.
18. Hertel A, Baum RP, Auerbach B et al. The clinical relevance of human anti-mouse-antibody (HAMA) in immunoscintigraphy. Nuklearmedizin 1990; 29: 221-7.
19. Ten Berge RJM, Natarajan AT, Hardeman MR et al. Labelling with Indium-111 has detrimental effects on human lymphocytes: concise communication. J Nucl Med 1983; 24: 615-20.
20. McKay DR, Bautovich GJ, Wilson MR et al. The effect of circulating antigens on radioimmunodetection and monoclonal antibody localization: studies in a normal rat model. Eur J Nucl Med 1989; 15: 313-20.
21. Morgan DA, Ruscetti F, Gallo R. Selective in vitro growth factor of T lymphocytes from normal human bone marrow. Science 1976; 193: 1007-9.
22. Robb RJ, Munck A, Smith KA. T-cell growth factor receptors: quantitation, specificity and biological relevance. J Exp Med 1981; 154: 1455-74.
23. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol 1983; 130: 2203-8.
24. Koths K, Halenbeck R. Pharmakokinetic studies on 35S- labelled recombinant interleukin-2 in mice. In: Sorg C, Schimtl A, Landy M eds. Cellular and molecular biology of lymphokines. Orlando: Academic Press, 1985: 779-83.
25. Muhlradt PF, Opit HC. Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. Eur J Immunol 1982; 12: 983-5.
26. Lampeter EF, Signore A, Gale EA et al. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 703-8.
27. Signore A, Pozzilli P, Gale EAM et al. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia 1989; 32: 282-9.
28. Signore A, Cooke A, Pozzilli P et al. Class-II and IL2 receptor positive cells in the pancreas of NOD mice. Diabetologia 1987; 30: 902-5.
29. Hodgkinson SC, Landon J, Lowry PJ. A liquid-phase two- site immunoradiometric assay for human prolactin. Biochem J 1984; 217: 273-9.
30. Osawa H, Diamantstein T. A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL receptor functions: a putative anti-IL 2 receptor antibody. J Immunol 1984; 132: 2445-50.
31. Signore A, Parman A, Pozzilli P et al. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: an early sign of type 1 diabetes. Lancet 1987; 2: 537-40.
32. Signore A, Sensi M, Pozzilli C et al. Effect of unlabeled indium oxine and indium tropolone on the function of isolated human lymphocytes. J Nucl Med 1985; 26: 612-15.
33. Bosslet K, Auerbach B, Hoffken H et al. Frequency and relevance of the human anti-mouse immunoglobulin (HAMA) response in immunoscintigraphy. Nucl Med 1990; 28: 149-56.
34. Ju G, Collins, L, Kaffka KL et al. Structure function analysis of human IL2. Identification of aminoacid residues required for biological activity. J Biol Chem 1987; 262: 5725-31.
35. Robb RJ, Mayer PC, Garlick R. Retention of biological activity following radioiodination of human interleukin-2: comparison with biosynthetically labelled growth factor in receptor binding assay. J mmunol Meth 1985; 81: 15-30.
36. Signore A, Beverley PCL, Parman A et al. Labelling of interleukin-2 (IL2) with 123-iodine with retention of its capacity to bind to activated lymphocytes. Exp Clin Endocrinol 1987; 89: 301-6.
37. Makino S, Kunimoto K, Muraoka Y et al. Breeding of a non-obese, diabetic strain of mice. Exp Anim 1980; 29: 1-10.
38. Collins KL. Species specificity of interleukin 2 binding to individual receptor components. Eur J Immunol 1989; 19: 1517-20.
39. Donohue JH, Lotze MT, Robb RJ et al. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res 1984; 44: 1380-6.